If you have more questions
This study has been replicated in variations (different tendons, different injury models) primarily within the Zagreb lab
AOD-9604 + CJC-1295 + Ipamorelin (12mg Blend Vial) Dosage Protocol Lipolytic hGH fragment (AOD-9604) + GHRH analog (CJC-1295) + GH secretagogue (Ipamorelin) in one 12 mg blend research-only, not FDA-approved
BPC-157 has been thoroughly researched for its therapeutic potential in a variety of conditions, including musculoskeletal injuries, digestive disorders, neurological conditions, autoimmune diseases, and skin and soft tissue injuries
Enough to make your dose easy to measure without overfilling the syringe
Half-life and mechanism descriptions reflect published literature approximations